Cancer Archives

OncoDNA Biosequence Moncodaneum Cancer Big Data

News and Trends 18 Oct 2017

Belgian Biotech Gathers Major Oncology Centers to Tackle Cancer with Big Data

OncoDNA is gathering prestigious oncology centers to take part in Moncodaneum, an international project to bring precision medicine to cancer patients. The Belgian biotech OncoDNA has announced that it will be collaborating with the Strasbourg University Hospital, France, and the Oncology Center of Bydgoszcz, Poland, in the advancement of precision medicine for cancer. The two […]

October 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Infographics 18 Oct 2017

Infographic: What is CAR-T Cell Therapy & How Does it Fight Cancer?

Everything you need to know about CAR-T, a revolutionary cell therapy for cancer. You might have heard of CAR-T cell therapy as a “miracle cure” for cancer. The approval of Novartis’ Kymriah, the first CAR-T therapy, made headlines in August as it was the first gene-edited cell therapy for cancer to make it to the […]

October 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 9 Oct 2017

The Woman Developing the Next Generation of Cancer Immunotherapy

Özlem Türeci discusses the future of individualized cancer therapy and her journey to become an entrepreneur and take science to patients. As a trained physician and immunologist, Dr. Özlem Türeci has led her own research group with Prof. Ugur Sahin at the University of Mainz, Germany, since 2000. But academic research was not enough for her, […]

October 9, 2017 - 8 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Oct 2017

Study Reveals No Evidence to Support Most European Cancer Drug Approvals

A new study concludes the majority of cancer drugs approved by the EMA between 2009 and 2013 weren’t backed by sufficient evidence that they are effective. A team of researchers from King’s College London and the London School of Economics has published a new study reviewing the clinical data used to back the approval of […]

October 6, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Oct 2017

British Biotech To Raise £12.2M to Finish Off Liquid Biopsy Technology

Angle will raise £12.2M, which will allow it to acquire assets from Axela to put the finishing touches to its full liquid biopsies solution. Angle is a leader in the liquid biopsy market, the ‘holy grail’ of cancer diagnostics. The company has developed technology that recently outperformed the gold standard in the field. Angle is hoping to raise £12.2M […]

October 5, 2017 - 3 minutesmins - By Alex Dale

immatics amgen fundraising cancer immunotherapy

News and Trends 4 Oct 2017

Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy

Immatics has completed a $58M (€50M) round with the participation of Amgen, not long after both companies signed a billion-dollar partnership. Immatics, a company based in Tübingen specialized in cancer immunotherapy, has announced that its Series E round has reached $58M (€50M). Existing investors including dievini Hopp Biotech, Wellington Partners, and AT Impf took part in the fundraising, which […]

October 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

ulf grawunder nbe therapeutics interview

Interview 4 Oct 2017

4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology

ADC development has progressed to the fourth generation. Serial entrepreneur Ulf Grawunder told me what NBE is doing differently from its predecessors. Ever since the first antibody-drug conjugate (ADC) was approved in 2001, there has been a lot of excitement about the technology. “Some people even referred to ADCs as a ‘magic bullet,’” recalls Ulf […]

October 4, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 28 Sep 2017

German Pharma Enters the Clinic with Solid Tumor Treatment

A Phase I study will investigate the safety and tolerability of Immatics approach to treating solid tumors. Immatics is a German biopharma based in Tuebingen, which is a leader in the field of cancer immunotherapy. It has announced today the initiation of a Phase I trial that will test the safety and tolerability of its […]

September 28, 2017 - 2 minutesmins - By Alex Dale

Interview 28 Sep 2017

What are Alphabodies and How Do They Drug the Undruggable?

Philip found out more about a new form of protein therapeutics being developed by Complix, which aims to drug the undruggable. Mark Vaeck, Co-Founder and CEO of Complix, has over 25 years experience in the biotech and pharma industries. His latest company Complix, a Belgian immuno-oncology biotech, is developing Alphabodies, tiny therapeutic proteins that can […]

September 28, 2017 - 3 minutesmins - By Alex Dale

News and Trends 26 Sep 2017

British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies

Autolus, based in London, has raised €68M in Series C to continue developing its T cell immunotherapies for cancer treatment. Autolus focuses on developing engineered T cell immunotherapies to beat cancer. Its pipeline includes therapies targeted at both hematological cancers and solid tumors. The Series C fundraising of $80M (€68M) is added to £70M (€80M) made in Series A […]

September 26, 2017 - 3 minutesmins - By Alex Dale

News and Trends 25 Sep 2017

Belgian Biotech Gets €1M Grant to Boost its mRNA Cancer Immunotherapies

Flanders Innovation and Entrepreneurship has given eTheRNA a €1M grant to further improve its TriMix mRNA cancer therapies. eTheRNA has been awarded the €1M industrial R&D projects grant by Flanders Innovation and Entrepreneurship. The company’s technology uses mRNA that stimulates the immune system to effectively treat cancer, giving rise to long-lasting remission in patients. It will […]

September 25, 2017 - 1 minutemin - By Alex Dale

News and Trends 21 Sep 2017

European Commission Approves Merck’s PD-L1 Inhibitor for Aggressive Skin Cancer

Merck and Pfizer’s new immunotherapy, avelumab, has been approved by the European Commission to treat metastatic Merkel cell carcinoma, an aggressive form of skin cancer. The approval is based on data from a Phase II study, JAVELIN Merkel 200, where subjects responded well to treatment for a sustained period of time. Earlier this year, Avelumab was […]

September 21, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Belgian Biotech Gathers Major Oncology Centers to Tackle Cancer with Big Data

Infographic: What is CAR-T Cell Therapy & How Does it Fight Cancer?

The Woman Developing the Next Generation of Cancer Immunotherapy

Study Reveals No Evidence to Support Most European Cancer Drug Approvals

British Biotech To Raise £12.2M to Finish Off Liquid Biopsy Technology

Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy

4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology

German Pharma Enters the Clinic with Solid Tumor Treatment

What are Alphabodies and How Do They Drug the Undruggable?

British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies

Belgian Biotech Gets €1M Grant to Boost its mRNA Cancer Immunotherapies

European Commission Approves Merck’s PD-L1 Inhibitor for Aggressive Skin Cancer

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!